LABU241213C114500
- 4.10
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Vir Gets FDA Breakthrough Therapy Status for Two Drugs
Thursday Ends in Index Declines | Wall Street Today
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites
$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Incyte's Late-Breaking ASH 2024 Data Show Tafasitamab (Monjuvi) Significantly Improves Progression-Free Survival In Relapsed/Refractory Follicular Lymphoma, Meeting Phase 3 InMIND Trial Endpoints; U.S. SBLA Filing Planned By Year-End 2024
B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target
Gilead Sciences Analyst Ratings
Gilead Company Kite Reports Results From Five-year Follow-up Analysis Of ZUMA-5, A Phase 2 Study Of Yescarta
Kite, A Gilead Company Presents Longest Follow-Up Data Reported For Tecartus CAR T-Cell Therapy At ASH 2024 Reinforce Durable Efficacy And Survival Benefits; ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, In...
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Monday Market Falls, Chinese Stocks Climb, Indices Rebalance | Live Stock
Reported Sunday, Gilead's Kite Highlights New Data Showcasing Yescarta's Curative Potential In Relapsed/Refractory Large B-Cell Lymphoma At ASH 2024
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
Incyte Announced Results From Phase 3 Trial Evaluating Retifanlimab In Combination With Platinum-based Chemotherapy In Patients With Non-small Cell Lung Cancer At ESMO Congress; Said Phase 3 POD1UM-304 Trial Met Primary Endpoint Of Overall Survival...